JSJanelle Wesleyn Salameh

Janelle Wesleyn Salameh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Janelle Wesleyn Salameh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Targeted IL-27-based gene therapy in preventing SARS-CoV-2 entry

    by Grace E. Mulia, Janelle W. Salameh, Marxa L. Figueiredo

  • Open Access

    Targeted IL-27-based gene therapy in preventing SARS-CoV-2 entry

    by Grace E. Mulia, Janelle W. Salameh, Marxa L. Figueiredo

    Background: Coronaviruses such as SARS-CoV and SARS-CoV-2 have caused severe respiratory syndromes and prominent global health crises over the past two decades. Despite vaccines and antiviral therapies, treatment limitations persist, particularly in preventing viral entry and addressing emerging variants. ACE2, the primary receptor for SARS-CoV-2, represents a critical target for intervention. Cell-based approaches, including mesenchymal stromal cell therapies, have shown safety and promise in clinical trials. Building on our prior success with IL-27 gene therapy for acute respiratory distress syndrome, we explored ACE2-targeted IL-27 delivery as a potential strategy to reduce SARS-CoV-2 entry. Methods and Results: We developed an in vitro model using SARS-CoV-2 spike pseudotyped lentivirus to mimic viral entry. Human adipose-derived stromal cells were electroporated with plasmid DNA encoding either ACE2-targeted or non-targeted IL-27, and conditioned media were collected. Two regimens were tested: “prevention,” where cells were pre-treated with conditioned media before viral exposure, and “treatment,” where conditioned media and pseudotyped virus were added simultaneously. Viral entry was quantified using luciferase reporter activity and genome copy units in HEK293-ACE2 and A549-ACE2 cells. ACE2-targeted IL-27 showed a concentration-dependent trend toward reduced lentiviral entry, particularly in A549-ACE2 cells, although differences were not statistically significant. Conclusions: These findings provide proof-of-concept that ACE2-targeted IL-27 stromal cell-based gene therapy may help inhibit SARS-CoV-2 entry. Further optimization of dosing, delivery platforms, and testing in models that assess viral replication and inflammation, as well as evaluation against spike variants, are warranted to explore its potential as an adjunct to COVID-19 treatments.

  • Open Access

    A Second-Generation Nanoluc-IL27 Fusion Cytokine for Targeted-Gene-Therapy Applications

    by Janelle Wesleyn Salameh, Shreya Kumar, Cosette Marie Rivera-Cruz, Marxa Leao Figueiredo

    An emerging approach in treating skeletal malignancies utilizes osteoimmunology to investigate new multifunctional immune-stimulatory agents that can simultaneously combat tumor growth and promote bone repair. We have hypothesized that cytokine Interleukin-27 (IL-27) is an excellent candidate biologic to help rebalance the prostate tumor cells and bone cell environment. In this work, we examined the proof of principle for a short, secreted luciferase (Nanoluc or Nluc) fusion with IL-27 to produce a novel cytokine-based biologic (Nluc-27), whereby we examined its efficacy in vitro in reducing prostate tumor growth and rebalancing bone cell proliferation and differentiation. This work demonstrates the targeting and anti-tumor efficacy of the Nluc-27 fusion cytokine in cancer and bone cell models. The fusion cytokine is detectable in conditioned media, and bioactive in different cell systems. This novel Nluc-27 cytokine will allow flexible incorporation of other targeting domains and may serve as flexible tool to augment IL-27′s bioactivity and reengineer its efficacy against prostate tumor or bone cells, and may prove applicable to several other cell types for targeted gene therapy applications.


  • Open Access

    Interleukin-27 Gene Delivery Targeting IL-6Rα-Expressing Cells as a Stress Response Therapy

    by Manoel Figueiredo Neto, Shengzhi Liu, Janelle Wes Salameh, Hiroki Yokota, Marxa Leão Figueiredo

    Interleukin-27 (IL-27) has shown promise in halting tumor growth and mediating tumor regression in several models, including prostate cancer. We describe our findings on the effects of IL-27 on the gene expression changes of TC2R prostate adenocarcinoma cells. We utilized RNAseq to assess profile differences between empty vector control, vector delivering IL-27 modified at its C-terminus with a non-specific peptide, and IL-27 modified at the C-terminus with a peptide targeting the IL-6-Rα. The targeted IL-27 had higher bioactivity and activity in vivo in a recent study by our group, but the mechanisms underlying this effect had not been characterized in detail at the gene expression level on tumor cells. In the present work, we sought to examine potential mechanisms for targeted IL-27 enhanced activity directly on tumor cells. The targeted IL-27 appeared to modulate several changes that would be consistent with an anti-tumor effect, including upregulation in the Interferon (IFN) and Interferon regulatory factor (IRF), oxidative phosphorylation, Janus kinase/Signal transducers and activators of transcription (JAK/STAT), and eukaryotic initiation factor 2 (EIF2) signaling. Of these signaling changes predicted by ingenuity pathway analyses (IPA), the novel form also with the highest significance (-log(Benjamini–Hochberg (B-H)) p-value) was the EIF2 signaling upregulation. We validated this predicted change by assaying for eukaryotic initiation factor 2 alpha (eIF2α), or phosphorylated eIF2α (p-eIF2α), and caspase-3 levels. We detected an increase in the phosphorylated form of eIF2α and in the cleaved caspase-3 fraction, indicating that the EIF2 signaling pathway was upregulated in these prostate tumor cells following targeted IL-27 gene delivery. This approach of targeting cytokines to enhance their activity against cancer cells is a novel approach to help augment IL-27′s bioactivity and efficacy against prostate tumors and could be extended to other conditions where it could help interfere with the EIF2α pathway and promote caspase-3 activation.


  • Open Access

    Polymer‐mediated gene therapy: Recent advances and merging of delivery techniques

    by Janelle W. Salameh, Le Zhou, Sarah M. Ward, Cristiam F. Santa Chalarca, Todd Emrick, Marxa L. Figueiredo

    The ability to safely and precisely deliver genetic materials to target sites in complex biological environments is vital to the success of gene therapy. Numerous viral and nonviral vectors have been developed and evaluated for their safety and efficacy. This study will feature progress in synthetic polymers as nonviral vectors, which benefit from their chemical versatility, biocompatibility, and ability to carry both therapeutic cargo and targeting moieties. The combination of synthetic gene carrying constructs with advanced delivery techniques promises new therapeutic options for treating and curing genetic disorders.This article is characterized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies


  • Top Cited Papers

    Physical characterization of nanoparticle size and surface modification using particle scattering diffusometry

    by Katherine N. Clayton, Janelle W. Salameh, Steven T. Wereley, Tamara L. Kinzer-Ursem

    As the field of colloidal science continues to expand, tools for rapid and accurate physiochemical characterization of colloidal particles will become increasingly important. Here, we present Particle Scattering Diffusometry (PSD), a method that utilizes dark field microscopy and the principles of particle image velocimetry to measure the diffusivity of particles undergoing Brownian motion. PSD measures the diffusion coefficient of particles as small as 30 nm in diameter and is used to characterize changes in particle size and distribution as a function of small, label-free, surface modifications of particles. We demonstrate the rapid sizing of particles using three orders-of-magnitude less sample volume than current standard techniques and use PSD to quantify particle uniformity. Furthermore, PSD is sensitive enough to detect biomolecular surface modifications of nanometer thickness. With these capabilities, PSD can reliably aid in a wide variety of applications, including colloid sizing, particle corona characterization, protein footprinting, and quantifying biomolecule activity.